Nikola Trbovic, a GCV Rising Stars Awards winner while principal at Pfizer Ventures, US-based pharmaceutical group Pfizer’s corporate venture capital unit, has joined venture capital firm SV Health Investors.
As a partner at SV, led by managing partner Kate Bingham, who devised the UK’s covid-19 vaccine strategy, Trbovic will be a biotech investor focused on funding companies working on transformative new therapeutics.
Trbovic’s investments at Pfizer Ventures, which he joined in 2014, had included Triplet Therapeutics, TRex Bio, Lodo Therapeutics, Complexa, Arrakis, Artios, Cydan, Jnana, Nimbus and Palleon.
For his 2019 award, Trbovic said: “My greatest success so far has probably been the impact I have had on setting up the R&D Innovate initiative – a $25m a year expansion of the CVC activities at the time dedicated to highly strategic investment opportunities – the success of which was a big part of our ability to argue for the integration and further expansion of Pfizer’s CVC activities.”
